Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors
- PMID: 15018896
- DOI: 10.1016/j.semcancer.2003.09.019
Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors
Abstract
VPF/VEGF is a multi-functional cytokine with important roles in both vasculogenesis and angiogenesis. Its production is generally regulated by local oxygen concentration. Hypoxia stimulates VPF/VEGF production by increasing its gene transcription and the stability of its mRNA. The increase in transcription in hypoxia occurs mainly through the stabilization and activation of the transcription factor, Hypoxia Inducible Factor (HIF). Cellular oxygen concentration is not the only regulator of VPF/VEGF synthesis. Some cancer cells can produce high levels of VPF/VEGF even in normoxia. Clear cell renal carcinoma cell line (RCC) like 786-0, pancreatic carcinoma cell line, ASPC-1, fibrocarcinoma cell line, HT1080, ovarian cancer cells, etc. produce an elevated level of VPF/VEGF, which is not dependent on hypoxia. In this article, we discuss different regulatory pathways in tumor cells comprised of oncogenes, tumor suppressor genes etc. that play important roles, in both the transcription and stability of VPF/VEGF mRNA.
Similar articles
-
Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.Cancer Res. 2001 Oct 1;61(19):7349-55. Cancer Res. 2001. PMID: 11585776
-
Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.Oncogene. 2000 Nov 16;19(48):5435-43. doi: 10.1038/sj.onc.1203938. Oncogene. 2000. PMID: 11114720
-
Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma.Cancer Res. 2001 Sep 15;61(18):6952-7. Cancer Res. 2001. PMID: 11559575
-
Angiogenesis: how a tumor adapts to hypoxia.Biochem Biophys Res Commun. 1999 Dec 29;266(3):718-22. doi: 10.1006/bbrc.1999.1889. Biochem Biophys Res Commun. 1999. PMID: 10603309 Review.
-
The von Hippel-Lindau tumor suppressor gene.Exp Cell Res. 2001 Mar 10;264(1):117-25. doi: 10.1006/excr.2000.5139. Exp Cell Res. 2001. PMID: 11237528 Review.
Cited by
-
Mutant copper-zinc superoxide dismutase associated with amyotrophic lateral sclerosis binds to adenine/uridine-rich stability elements in the vascular endothelial growth factor 3'-untranslated region.J Neurochem. 2009 Feb;108(4):1032-44. doi: 10.1111/j.1471-4159.2008.05856.x. J Neurochem. 2009. PMID: 19196430 Free PMC article.
-
Silencing of Rac1 expression via RNA interference inhibits retinal neovascularization in rats.Mol Vis. 2012;18:1354-60. Epub 2012 May 30. Mol Vis. 2012. PMID: 22690113 Free PMC article.
-
Mutant Cu/Zn-superoxide dismutase associated with amyotrophic lateral sclerosis destabilizes vascular endothelial growth factor mRNA and downregulates its expression.J Neurosci. 2007 Jul 25;27(30):7929-38. doi: 10.1523/JNEUROSCI.1877-07.2007. J Neurosci. 2007. PMID: 17652584 Free PMC article.
-
Molecular pathology of eyes with von Hippel-Lindau (VHL) Disease: a review.Retina. 2007 Jan;27(1):1-7. doi: 10.1097/01.iae.0000244659.62202.ee. Retina. 2007. PMID: 17218907 Free PMC article. Review.
-
Vascular Endothelial Growth Factor Receptor-1 Modulates Hypoxia-Mediated Endothelial Senescence and Cellular Membrane Stiffness via YAP-1 Pathways.Front Cell Dev Biol. 2022 Jul 1;10:903047. doi: 10.3389/fcell.2022.903047. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35846360 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
